Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...

Vertex Pharmaceuticals got a fresh boost of confidence from H.C. Wainwright, which reaffirmed its Buy rating after the ADA ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C.

The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...